CVS Caremark adds Zepbound and Foundayo to formulary

CVS Caremark will restore coverage of Eli Lilly's Zepbound by Oct. 1 and add Lilly's oral weight loss pill Foundayo to standard commercial formularies starting June 1 for plans that opt in. The change gives Lilly and Novo Nordisk co-preferred status on CVS's formulary and is expected to cut weight-management drug spending by another 10% to 15%. The move improves access and is positive for Lilly, while potentially intensifying competition in the obesity drug market.

Analysis

CVS is signaling that formulary management is shifting from pure exclusion to monetized coexistence: the PBM has learned that blocking the highest-demand GLP-1s creates litigation, member churn, and employer dissatisfaction that can outweigh rebate gains. The key second-order effect is that access broadens, but utilization management likely tightens elsewhere — higher prior-auth friction, higher step edits, and more aggressive dose optimization — so the headline is positive for volume but not necessarily for net pricing power across the category.

For Lilly, the bigger incremental win is not the slot itself but the normalization of Zepbound as a “must-carry” product in employer benefit design. That improves the odds of higher script persistence and less category switching, which matters more than a one-time formulary change because obesity drugs are a retention game: once a patient stabilizes, refill duration can run for many months. The oral product adds an even more scalable access vector, but its economics will likely pressure the entire class toward lower effective net prices faster than investors expect.

For Novo, this is a mild relative negative because the prior CVS preference was a meaningful commercial moat, and losing exclusivity at a major PBM increases the risk that Wegovy’s rebate economics must compress further to defend share. The contrarian risk is that the market may be underestimating how quickly pharmacy benefit managers can reset the pricing corridor lower: if two manufacturers are now co-preferred, the next negotiation round likely shifts value from gross revenue to incremental lives covered, which is bearish for long-term margin expansion in obesity. Litigation also remains a latent overhang for CVS, because any future access rollback after public normalization would be harder to defend politically and legally.

Key Decisions for Investors

• Long CVS / short NVO over the next 1-3 months: CVS should capture near-term sentiment relief and improved employer relations, while NVO faces a modest share and rebate-pressure setback; target a 5-8% relative move, stop if Novo signals materially better-than-expected U.S. demand retention.
• Buy CVS call spreads 1-2 months out: express upside from formulary optics and reduced litigation headline risk with limited premium outlay; structure for a 2:1 to 3:1 payoff if management highlights employer adoption in the next earnings cycle.
• Add to LLY on weakness for a 3-6 month horizon: the re-admission of Zepbound is a volume-duration positive and reduces the probability of prolonged PBM exclusion risk; favor stock over calls because the catalyst is gradual, not binary.
• Short a basket of obesity adjacent beneficiaries on any broad rally — especially names levered to GLP-1 scarcity narratives — because wider access tends to compress referral premiums and channel conflict; use a 2-4 week horizon after the formulary effective dates.
• Watch for a follow-on bearish signal in PBM earnings commentary: if CVS/ESI/Optum all point to deeper obesity category rebate cuts, that would confirm a multi-quarter margin reset and justify increasing underweights in NVO and other high-expectation weight-loss exposures.